Zobrazeno 1 - 10
of 137
pro vyhledávání: '"John E. Janik"'
Autor:
Andrey Moiseyenko, Franco Muggia, Thomas Condamine, Jennifer Pulini, John E. Janik, Daniel C. Cho
Publikováno v:
Gynecologic Oncology Reports, Vol 34, Iss , Pp 100655- (2020)
Agonists of the co-stimulatory molecule OX40 (CD134) are in clinical assessment alone and in combination with other immunotherapies. Recent pre-clinical studies have suggested that concurrent administration of OX40 agonists with anti-PD1 therapy is d
Externí odkaz:
https://doaj.org/article/f54232bc75be42ceab3234f9584b60f7
Autor:
Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, N
Externí odkaz:
https://doaj.org/article/fa3f41ad888d41f5a1c759f8b6fa21b2
Autor:
Weixin Wang, Meghan Corrigan-Cummins, Justin Hudson, Irina Maric, Olga Simakova, Sattva S. Neelapu, Larry W. Kwak, John E. Janik, Barry Gause, Elaine S. Jaffe, Katherine R. Calvo
Publikováno v:
Haematologica, Vol 97, Iss 4 (2012)
Background MicroRNAs can play an important role in tumorigenesis through post-transcriptional regulation of gene expression, and are not well characterized in follicular lymphoma.Design and Methods MicroRNA profiles of enriched follicular lymphoma tu
Externí odkaz:
https://doaj.org/article/9d56f0d8745d44dc992f50697bb5b6c1
Autor:
David Ritchie, Richard L. Piekarz, Piers Blombery, Laszlo J. Karai, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, John E. Janik, H. Miles Prince, Susan E. Bates
Publikováno v:
Haematologica, Vol 94, Iss 11 (2009)
Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. A phase II study exploring the efficacy of romidepsin, an histone
Externí odkaz:
https://doaj.org/article/401b12a30f4b47279b13d81712e74da2
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Effects of the combination therapy of anti-OX40 and anti-PD-1 Abs with tumor vaccine on spleen and tumor T-cell infiltration and clonality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44c63ff14df19403c3f2a7fca5a301e1
https://doi.org/10.1158/2326-6066.22539581
https://doi.org/10.1158/2326-6066.22539581
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1) together with immune stimulatory agonist Abs like anti-OX40 are being tested in the clinic to achieve improved antitumor effects. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c0801e54b2055f9ba4cd12f3c386703
https://doi.org/10.1158/2326-6066.c.6549134.v1
https://doi.org/10.1158/2326-6066.c.6549134.v1
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615d975cb0e07c871f0a46f68a354f77
https://doi.org/10.1158/2326-6066.22539587
https://doi.org/10.1158/2326-6066.22539587
Autor:
John C. Morris, Thomas A. Waldmann, Seth M. Steinberg, Cathryn C. Lee, Thomas A. Fleisher, Mark Raffeld, Elaine S. Jaffe, Maryalice Stetler-Stevenson, Stefania Pittaluga, Donn Stewart, Deirdre O'Mahony, John E. Janik, Kamal Sharma
Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8747d5d14eeaed03679515d841c40821
https://doi.org/10.1158/1078-0432.22467129
https://doi.org/10.1158/1078-0432.22467129
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8503f7c52a990afce6ce287288e5ed31
https://doi.org/10.1158/1078-0432.22440441.v1
https://doi.org/10.1158/1078-0432.22440441.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Purpose: We report an increased incidence of EBV-induced B-cell lymphoproliferative disease (LPD) in patients treated with siplizumab, an anti-CD2 antibody. The development of EBV-LPD has been associated with the use of immunosuppressive agents used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac91bb7565e1e40c0a53634257bdd81
https://doi.org/10.1158/1078-0432.c.6517770.v1
https://doi.org/10.1158/1078-0432.c.6517770.v1